InvestorsHub Logo
Followers 67
Posts 3828
Boards Moderated 0
Alias Born 11/23/2014

Re: None

Monday, 12/04/2017 4:27:33 PM

Monday, December 04, 2017 4:27:33 PM

Post# of 106822
$USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 Assets,~X3.5 Cash from Sept 2016-2017, and look to be set up for a move to new highs. USRM brought in $1.5 million in revs & $1 million of gross profit last Q alone

http://www.nasdaq.com/symbol/usrm/revenue-eps

That link above paints a clear picture of where the company is headed

There is so much more going for the company now versus earlier this year when it was trading with a VWAP between $.075-$.14 for 80+ trading days and especially last year or what ever happened almost ten years ago. I am looking forward to more and more revenue growth with overseas expansion with their Kuwait clinic and hopefully more trials and updates on RMAT. One big spark and the game changes.

A $16 million market cap @ $.045 could easily be $100mil market cap which would be ~$.30/share. A valuation correction is well over due if you ask me and it seems others are beginning to agree.

They doubled revs and tripled profits in 1 year and the stem cell market is growing at an insane rate.
https://www.ihealthcareanalyst.com/global-stem-cell-therapy-market/ Mentioned here as Bioheart
"The global stem cells market was approximately 13 billion dollars in 2016, and from 2017, the expected annual growth rate is 14.7%, which would expand the market to 29.6 billion dollars by 2021."
"Major players operating in the global stem cell therapy market and profiled in this report include Aastrom Biosciences, Alliancells Bioscience Co. Ltd., AlloCure, Inc., Anterogen Co. Ltd., Astellas Pharma (Ocata Therapeutics/Advanced Cell Technology), Baxter Healthcare, Bioheart, BrainStorm Therapeutics, Caladrius Biosciences, Cardio3 Sciences, Cellonis Biotechnology, Cytori Therapeutics, FCB-Pharmicell Co. Ltd., Gamida Cell, Geron Corporation, LifeCell, Ixion Biotechnology, Medipost Co. Ltd., Mesoblast, Neuralstem, Inc., NeuroGeneration, Inc., NuVasive, Inc., Orthofix, Osiris Therapeutics, Pfizer, ReNeuron, Skye Orthbiologics, LLC, Stem Cell Therapeutics, STEMCELL Technologies, StemCells, Inc., Stemedica Cell Technologies, Inc., Stempeutics Research, TiGenix, and ViaCyte."

& here
https://globenewswire.com/news-release/2017/09/20/1125383/0/en/Stem-Cells-Market-to-reach-US-270-5-bn-by-2025-globally-Transparency-Market-Research.html
Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc

& this report

https://www.prnewswire.com/news-releases/global-stem-cell-therapy-for-osteoarthritis-pipeline-analysis-report-2017-300549315.html
"The expected growth is because of increasing awareness of osteoarthritis and increasing diagnosis rates, rising older population, and increasing cases of obesity. Osteoarthritis is directly related to obesity, with approximately 37% of osteoarthritis patients suffering from obesity.

Major companies

Mesoblast
Regeneus
U.S. Stem Cell
Anterogen
Asterias Biotherapeutics"

& a lot more is out there.
$USRM is on track for a $8-$10 million rev 2018 year even if growth slows.


BELOW ARE USRM's Key growing FINANCIALS in simple form
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
$1700k Sept 2017

Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k vs 443k last Jun 2016)
$1507k Sept 2017 (Gross profit now $1024k vs $397k last Sept 2016)

Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
$957k Sept 2017

2016 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11674975
2017 Q1 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12033381
2017 Q2 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12218852
2017 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12365541

#USRM #STEMCELLS #FDA $USRM

Everything is in my own opinion. Do what you think is right.